Demand for COVID-19 tests exceeds production: Roche
The drugmaker has said that it aims to more than double production of antibody tests to well over 100 million a month by the end of the year.
Vienna: Swiss drugmaker Roche is unable to meet the demand for molecular tests to identify active COVID-19 infections, its chairman told Swiss daily Tagesanzeiger."The demand exceeds our production," Christoph Franz was quoted as saying in Saturday's paper. The decision on where tests were shipped to depended, among other things, on infection rates and the availability of...
Vienna: Swiss drugmaker Roche is unable to meet the demand for molecular tests to identify active COVID-19 infections, its chairman told Swiss daily Tagesanzeiger.
"The demand exceeds our production," Christoph Franz was quoted as saying in Saturday's paper. The decision on where tests were shipped to depended, among other things, on infection rates and the availability of diagnostic equipment.
Demand for its antibody tests, which determine whether people have ever been infected with the coronavirus, can be met as Roche has been boosting production, he said.
Read also: Roche, Entero Healthcare join hands for key nephrology drugs
Franz said that Roche had started research on a potential drug to treat COVID-19 but added that these efforts were at a very early stage.
Headquarters in Basel, Roche is a multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Read also: Roche, Cipla collaborate for key oncology drugs
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd